[Determination of brain natriuretic peptide levels and its N-terminal fragment for the evaluation of renal replacement therapies efficiency in patients with decompensated chronic heart failure]

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a clinical trial.

To compare the capabilities of identifying different types of brain natriuretic peptide (BNP) for the evaluation of renal replacement therapy modalities in patients with decompensated chronic heart failure (CHF).

Who Took Part

According to the abstract, 31 men were involved.

The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.

Patients (31 men and 9 women) aged 30 to 82 years with functional class II-IV CHF in its decompensation phase were examined.

The patients were divided into 2 groups.

How the Study Was Run

There were 4 examination stages [control study points (CSP)]: (1) before study; (2) after CHF compensation achievement (a day before hospital discharge); (3) following 90 days; (4) following 180 days.

The plasma concentration of active BNP was measured by enzyme immunoassay; that of the N-terminal fragment of BNP (NT-proBNP) was estimated on an analyzer.

What Was Measured

Topics PubMed links to this paper include Chronic Disease, Diuretics, Heart Failure, Hemofiltration, Kidney, Kidney Function Tests and Natriuretic Peptide, Brain.

What This Means in Plain Language

This is a clinical trial of BNP (Nesiritide) in 31 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (Terapevticheskii arkhiv), a journal based in Russia (Federation).

More context: the BNP (Nesiritide) compound page, all human trials.